Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer
Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer
复制标题
DOI：
10.1002/pros.10083
复制
发表时间：
2002-06-01
期刊：
影响因子：
2.8
通讯作者：
Bergh, A
中科院分区：
文献类型：
--
作者：
Wikström, P;Lissbrandt, IF;Bergh, A
背景内皮糖蛋白是转化生长因子-β（TGF-β）家族的一些成员的受体，在增殖的内皮细胞上表达，并且已被认为是正在进行的血管生成的标志物。在这项研究中，内皮糖蛋白被评估为前列腺癌进展的预后因素。在72例前列腺癌中检测了endoglin的免疫组化染色，并与泛内皮标志物von Willebrand因子（vWf）、临床病理因素和癌症特异性生存率的免疫组化染色进行了比较。在血管化程度最高的区域测量微血管。分别用抗平滑肌肌动蛋白和endoglin或vWf抗体进行双重染色，以评估血管成熟度。内皮素染色的肿瘤血管一般较小，只有19%也与肌动蛋白染色。内皮糖蛋白是一个更好的预后指标比vWf。肿瘤血管计数（vc）高于中位值的患者的中位生存时间短于vc低于中位值的患者（内皮糖蛋白和vWf分别为4 vs. 12年，P =0.0007和5 vs. 10年，P=0.018）。Endoglin vc与Gleason评分（P=0.001）、局部肿瘤分期（P=0.0006）、转移（P=0.01）、肿瘤细胞TGF-β 1免疫反应性（P=0.0003）和肿瘤细胞增殖指数（r（s）=0.319，P=0.02）相关。与vWf相比，Endoglin、vc对Gleason评分为5、6和7分的肿瘤患者亚组的生存率具有预后意义。内皮糖蛋白主要标记前列腺中可能新形成的小肿瘤血管，是前列腺癌患者有希望的预后标记物。
Background. Endoglin, a receptor for some of the members of the transforming growth factor-beta (TGF-beta) family, is expressed on proliferating endothelial cells and has been suggested as a marker of ongoing angiogenesis. In this study, endoglin was evaluated as a prognostic factor for prostate cancer progression.Methods. Immunohistochemical staining of endoglin was examined in 72 cases of prostate cancer and compared with immunohistochemical staining of the pan-endothelial marker von Willebrand factor (vWf), clinicopathological factors, and cancer-specific survival. Microvessels were measured in the most vascularized fields. Double staining with antibodies against smooth muscle actin and endoglin or vWf, respectively, was performed in order to evaluate vessel maturation.Results. Endoglin-stained tumor vessels were generally small and only 19% also stained with actin. Endoglin was a better prognostic marker than vWf. The median survival times were shorter for patients with tumor vascular count (vc) above median than for patients with vc below median (4 vs. 12 years, P=0.0007, and 5 vs. 10 years, P=0.018, for endoglin and vWf, respectively). Endoglin vc was associated with Gleason score (P=0.001), local tumor stage (P=0.0006), metastasis (P=0.01), tumor cell immunoreactivity for TGF-beta1 (P=0.0003), and tumor cell proliferation index (r(s)=0.319, P=0.02). Endoglin, in contrast to vWf, vc was prognostic for survival in the subgroup of patients with Gleason score 5, 6, and 7 tumors.Conclusions. Endoglin marks principally small, probably newly formed tumor vessels in zthe prostate, and is a promising prognostic marker for prostate cancer patients.